Sanofi-Aventis has announced positive results from a Phase III trial of cabazitaxel, an investigational compound, which showed significantly improved overall survival and progression-free survival in patients with advanced hormone-refractory prostate cancer.
The drug may provide hope for many patients with metastatic hormone-refractory prostate cancer whose disease continues to progress despite prior chemotherapy and for whom there are no approved therapies.
The TROPIC trial was designed to assess patients with metastatic hormone-refractory prostate cancer whose disease had progressed following treatment with docetaxel-based chemotherapy.
Results showed that the combination of cabazitaxel and prednisone/prednisolone significantly reduced the risk of death by 30%, with a clinically meaningful improvement in the median overall survival.
Full results will be presented in San Francisco, CA on 5 March at the 2010 Genitourinary Cancers Symposium.